Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 39Pancreatic Neoplasms 27Rectal Neoplasms 21Stomach Neoplasms 20Colonic Neoplasms 16Esophageal Neoplasms 11Neoplasm Metastasis 7Lymphoma, Large B-Cell, Diffuse 7Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Liver Neoplasms 4Cholangiocarcinoma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Prolymphocytic 2Glioblastoma 2Gastrointestinal Diseases 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

Nivolumab 9Ipilimumab 4linrodostat 2relatlimab 1regorafenib 1Tetanus Toxoid 1Sorafenib 1Paclitaxel 1Oxaliplatin 1N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Cancer × Oxaliplatin × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡